• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies.基于淋巴瘤生存改善联盟（CISL）及韩国临床研究的韩国边缘区淋巴瘤的器官特异性考量
Blood Res. 2019 Mar;54(1):4-6. doi: 10.5045/br.2019.54.1.4. Epub 2019 Mar 21.
2
Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.韩国血液学会淋巴瘤工作组淋巴瘤生存改善联盟开展的临床研究综述。
Blood Res. 2013 Sep;48(3):171-7. doi: 10.5045/br.2013.48.3.171. Epub 2013 Sep 25.
3
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.韩国淋巴瘤流行病学及真实临床领域，包括淋巴瘤生存改善联盟（CISL）试验。
Int J Hematol. 2018 Apr;107(4):395-404. doi: 10.1007/s12185-018-2403-9. Epub 2018 Jan 22.
4
Consortium for Improving Survival of Lymphoma (CISL): a model of multicenter collaboration for lymphoma studies in Korea.淋巴瘤生存改善联盟（CISL）：韩国淋巴瘤研究的多中心合作模式。
Blood Res. 2015 Dec;50(4):187-8. doi: 10.5045/br.2015.50.4.187. Epub 2015 Dec 21.
5
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.利妥昔单抗联合 CVP 方案化疗治疗晚期边缘区淋巴瘤的 II 期临床试验：改善淋巴瘤生存联盟（CISL）研究。
Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16.
6
Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.I/II期边缘区淋巴瘤经确定性局部治疗后进行额外化疗是否有作用？淋巴瘤生存改善联盟（CISL）研究。
Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.
7
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.R-CVP 方案Ⅱ期研究后行利妥昔单抗维持治疗晚期边缘区淋巴瘤患者：改善淋巴瘤生存（CISL）研究联盟。
Cancer Commun (Lond). 2019 Oct 16;39(1):58. doi: 10.1186/s40880-019-0403-7.
8
REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma.韩国恶性淋巴瘤的REAL分类：近期确认实体的发病率及临床病理特征变化。韩国病理学家协会血液淋巴网状组织研究组。修订的欧美淋巴瘤分类。
Cancer. 1998 Aug 15;83(4):806-12.
9
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.黏膜相关淋巴组织边缘区 B 细胞淋巴瘤——什么是预后因素，最佳治疗、手术还是化疗是什么：改善淋巴瘤生存研究联盟（CISL）研究。
Ann Hematol. 2010 Jun;89(6):563-8. doi: 10.1007/s00277-009-0875-7. Epub 2009 Dec 19.
10
Primary nodal marginal zone lymphomas of splenic and MALT type.脾脏和MALT型原发性淋巴结边缘区淋巴瘤。
Am J Surg Pathol. 1999 Jan;23(1):59-68. doi: 10.1097/00000478-199901000-00006.

本文引用的文献

1
Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study.治疗同步双侧眼部附属器边缘区淋巴瘤：改善淋巴瘤生存联合研究。
Ann Hematol. 2018 Oct;97(10):1851-1857. doi: 10.1007/s00277-018-3387-5. Epub 2018 Jun 11.
2
Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial.血小板与淋巴细胞比值（PLR）在接受利妥昔单抗、环磷酰胺、长春新碱和泼尼松联合化疗（R-CVP）治疗的晚期边缘区淋巴瘤患者中具有独立的预后意义：淋巴瘤生存改善联盟试验。
Blood Res. 2017 Sep;52(3):200-206. doi: 10.5045/br.2017.52.3.200. Epub 2017 Sep 25.
3
Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study.伴有不良因素的局限性眼附属器黏膜相关淋巴组织淋巴瘤的一线化疗免疫治疗：一项II期研究
Oncotarget. 2017 Aug 2;8(40):68583-68590. doi: 10.18632/oncotarget.19788. eCollection 2017 Sep 15.
4
Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung.肺黏膜相关边缘区 B 细胞淋巴瘤患者的治疗结果。
J Thorac Cardiovasc Surg. 2017 Jul;154(1):342-349. doi: 10.1016/j.jtcvs.2017.03.043. Epub 2017 Mar 21.
5
Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.I/II期边缘区淋巴瘤经确定性局部治疗后进行额外化疗是否有作用？淋巴瘤生存改善联盟（CISL）研究。
Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.
6
Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma.多西环素一线治疗既往未治疗的眼附属器边缘区B细胞淋巴瘤患者的长期预后。
Ann Hematol. 2015 Apr;94(4):575-81. doi: 10.1007/s00277-014-2240-8. Epub 2014 Oct 24.
7
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.利妥昔单抗联合 CVP 方案化疗治疗晚期边缘区淋巴瘤的 II 期临床试验：改善淋巴瘤生存联盟（CISL）研究。
Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16.
8
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.黏膜相关淋巴组织边缘区 B 细胞淋巴瘤——什么是预后因素，最佳治疗、手术还是化疗是什么：改善淋巴瘤生存研究联盟（CISL）研究。
Ann Hematol. 2010 Jun;89(6):563-8. doi: 10.1007/s00277-009-0875-7. Epub 2009 Dec 19.
9
Nongastric marginal zone B-cell lymphoma: analysis of 247 cases.非胃黏膜相关淋巴组织边缘区B细胞淋巴瘤：247例病例分析。
Am J Hematol. 2007 Jun;82(6):446-52. doi: 10.1002/ajh.20874.

Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies.

作者信息

Oh Sung Yong, Suh Cheolwon

机构信息

Department of Internal Medicine, Dong-A University Hospital, Busan, Korea.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

出版信息

Blood Res. 2019 Mar;54(1):4-6. doi: 10.5045/br.2019.54.1.4. Epub 2019 Mar 21.

DOI:10.5045/br.2019.54.1.4
PMID:30956956
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6439296/
Abstract
摘要